Comments from the Trump administration's top health official add to signs of a major flaw in the president's plans to set the best drug prices. These comments point to problems in Trump's initiatives to lower drug prices. The article also mentions Gilead's December 2025 deal with the White House, which affects its HIV portfolio. Gilead expects 6% growth in HIV drug sales in 2026 despite 2% headwinds from the Most Favored Nation agreement and the expiration of Obamacare. Sales of Gilead's HIV drugs will reach $20.8 billion in 2025, up 6% from 2024. Growth was driven by Biktarvy, whose sales rose 7% to $14.3 billion. Total sales of Gilead's products are expected in 2026 at the level of 29.6 to 30 billion dollars. CEO Daniel O'Day stated that with no major exclusivity losses until 2036, the business is stable and growing.[1]